Recent Updates
Recently added Catalysts
REGN

Regeneron’s ARCALYST (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-lowering Therapy Proportion of patients experiencing gout flares reduced from 45.2 percent to 14.6 percent

Thursday, September 4, 2008 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Regeneron’s ARCALYST (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-lowering Therapy Proportion of patients experiencing gout flares reduced from 45.2 percent to 14.6 percent

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+42%
120-day peak, hindsight
Typical move
2.7%
average across 15 past catalysts
Lead asset
REGN7508
Phase 3 · Venous Thromboembolism

Full Press Release Details

Regeneron’s ARCALYST (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-lowering Therapy Proportion of patients experiencing gout flares reduced from 45.2 percent to 14.6 percent.

Biotech snapshot

Cash runway
$17823M liquidity · $0M/mo burn
Low dilution risk
Lead asset
REGN7508Phase 3
Venous Thromboembolism →

Catalyst track record

+42%
best trade around REGN's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for REGN.

See every catalyst's timing & PoA →